Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ragifilimab in advanced or metastatic solid tumors
NCT02697591Phase 2Completed
- Sponsor
- Incyte
- Start
- Jun 2016
- Primary completion
- Dec 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of INCAGN1876 in solid tumor (advanced stage), metastatic solid tumor, endometrial adenocarcinoma, melanoma, non-small cell lung cancer (NSCLC), sponsored by Incyte. Started Jun 2016; status: completed.
02
Drugs
INCAGN1876
03
Conditions
solid tumor (advanced stage)metastatic solid tumorendometrial adenocarcinomamelanomanon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02697591.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02697591.